Rigorous studies are necessary to demonstrate suitability of metabolomics platforms to profile metabolites in archived plasma within epidemiologic studies of human disease, for which attenuation of effect estimates due to measurement error is a key concern.
High-throughput identification and quantification of small molecule metabolites produced by metabolism, or metabolomics, is increasingly used to evaluate alterations in metabolism and their relationship to human disease (1) (2) (3) (4) (5) . In epidemiologic studies, in which participants have provided information on a variety of exposures and diseases in addition to biological samples, metabolomics has particular potential to advance understanding of disease. Understanding sources of error in metabolite measurement is critical for epidemiologic studies because measurement error may lead to attenuation of metabolic profile-disease effect estimates and inhibit ability to detect true associations.
In addition to laboratory variability, other sources of error that may be unique to epidemiologic studies need to be considered (6, 7 ) . For example, when participants reside across a wide geographic area, peripheral blood can be drawn locally and mailed to a central laboratory for processing. Some circulating analytes may be unstable during delays in plasma processing, contributing to measurement error. Further, because of limited resources, many studies collect only a single biological sample from participants. Yet, if a single metabolite measurement is not representative of longerterm levels, a prospective epidemiologic investigation may miss an association between a metabolite profile and disease, particularly for diseases with long latency periods (6, 7 ) .
However, only limited data on reproducibility over processing delays and over time in archived plasma samples typical of epidemiologic studies are available for many of the metabolites measured by metabolomics platforms (8 -12 ) . We conducted 3 pilot studies to assess interassay reproducibility, reproducibility over delays in processing, and within-person reproducibility over time of over 250 plasma metabolites measured by a liquid chromatography-tandem mass spectrometry (LC-MS/MS) 6 metabolomics platform. These studies used archived biological samples donated by men and women enrolled in 2 large, prospective cohort studies as well as noncohort participant volunteers.
Materials and Methods

NURSES' HEALTH STUDY
The Nurses' Health Study (NHS) began in 1976 when 121 700 female registered nurses, age 30 -55 years, responded to a mailed questionnaire. In 1989 -1990, 32 826 participants arranged to have their blood collected in two 15-mL sodium heparin tubes and shipped the samples with an icepack in a Styrofoam container to our laboratory via overnight courier (13 ) . On arrival, blood samples were processed (i.e., centrifuged and divided into aliquots of plasma, white blood cell, and red blood cell components), and stored in the vapor phase of liquid nitrogen freezers at less than Ϫ130°C.
To assess within-person reproducibility of biological markers, a subset of 390 participants who returned a blood sample in 1989 -1990, were postmenopausal, had not used postmenopausal hormones for at least 3 months, and had no previous diagnosis of cancer (except nonmelanoma skin cancer), provided 2 additional blood samples in 1991-1992 using the same collection protocol and materials as in the initial collection.
HEALTH PROFESSIONALS FOLLOW-UP STUDY
The Health Professionals Follow-Up Study (HPFS) was initiated in 1986 when 51 529 male US dentists, pharmacists, veterinarians, podiatrists, and osteopathic physicians, age 40 -75 years, completed a mailed questionnaire. In 1993-1995, EDTA blood samples (three 10-mL tubes) were obtained from 18 225 participants (14 ) . Procedures for collecting, processing, and storing the samples were identical to those for the NHS samples. Table 2 . Briefly, the blinded duplicates pilot evaluated interassay reproducibility-overall, by anticoagulant type, and by fasting status-in duplicate samples from 30 NHS and HPFS participants and 20 replicate samples from 6 large QC pools (5 sodium heparin pools and 1 EDTA pool). The QC pools were created using discarded plasma from blood donation centers and interspersed randomly across the 3 pilot studies. The delayed processing pilot included 48 sam- ples donated by 12 individuals and evaluated reproducibility of metabolites in EDTA and sodium heparin whole blood samples that were processed and then frozen at less than Ϫ130°C immediately or after a 24-or 48-h delay. The within-person reproducibility over time pilot study evaluated whether a single metabolite measurement reasonably reflected a measurement obtained 1-2 years later. Previous studies have demonstrated that, within the context of epidemiologic studies, a small number of replicates obtained several years apart is useful to estimate the extent of attenuation in observed effect estimates due to within-person variability over time (7, (15) (16) (17) (18) (19) . For this pilot, we randomly selected 40 NHS participants who returned at least 2 separate blood samples, each collected at least 8 h after the last meal, over 1-2 years. To avoid bias in metabolite profiling, all analyzed samples, including QCs, were given alias identification numbers and randomly arranged. All study participants provided implied consent by returning the questionnaires and blood samples. The Institutional Review Board of Brigham and Women's Hospital approved these studies.
PILOT STUDIES
METABOLITE PROFILING
Profiles of endogenous polar metabolites and lipids were obtained using LC-MS/MS. The polar metabolite profiling methods were developed using reference standards of each metabolite to determine chromatographic retention times and MS multiple reactionmonitoring transitions, declustering potentials, and collision energies (See Tables 1-3 in the Data Supplement that accompanies the online version of this report at http://www.clinchem.org/content/vol59/issue11 for LC-MS/MS parameters for each method). Negative ionization mode data were acquired using an ACQUITY UPLC (Waters) coupled to a 5500 QTRAP triple quadrupole mass spectrometer (AB SCIEX) running a modified version of the hydrophilic interaction chromatography (HILIC) method described by Bajad et al. (20 ) . Plasma samples (30 L) were extracted using 120 L of 80% methanol (VWR) containing 0.05 ng/L inosine- White race/ethnicity, n (%) 30 (100) 7 (58) 40 (100) a Data from all QC samples were analyzed as part of the blinded duplicates pilot study. b Each participant's initial blood collection was divided into 3 aliquots. Four participants provided 3 heparin aliquots, 4 participants provided 3 EDTA aliquots, and 4 participants provided 3 heparin and 3 EDTA aliquots.
spray voltage was Ϫ4.5 kV and the source temperature was 500°C. Positive ionization mode data were acquired as in Wang et al. with a modification to the MS acquisition in which all multiple reaction-monitoring transitions were scheduled in a single method file (3 ) . Briefly, the LC-MS/MS system consisted of a 4000 QTRAP triple quadrupole mass spectrometer (AB SCIEX) coupled to an 1100 Series pump (Agilent) and an HTS PAL autosampler (Leap Technologies). Plasma samples (10 L) were extracted using 9 volumes of 74.9:24.9:0.2 (v/v/v) acetonitrile/methanol/formic acid containing stable isotope-labeled internal standards [0.2 ng/L valine-d8 (Isotec) and 0.2 ng/L phenylalanine-d8 (Cambridge Isotope Laboratories)]. The samples were centrifuged (10 min, 9000g, 4°C) and the supernatants (10 L) were injected onto a 150 ϫ 2.1-mm Atlantis HILIC column (Waters). The column was eluted isocratically at a flow rate of 250 L/min with 5% mobile phase A (10 mmol/L ammonium formate and 0.1% formic acid in water) for 1 min followed by a linear gradient to 40% mobile phase B (acetonitrile with 0.1% formic acid) over 10 min. The ion spray voltage was 4.5 kV and the source temperature was 450°C.
Lipids were profiled as described in Rhee et al. (21 ) . Briefly, plasma samples (10 L) were extracted for lipid analyses with 190 L of isopropanol containing 0.25 ng/L 1-dodecanoyl-2-tridecanoyl-sn-glycero-3-phosphocholine (Avanti Polar Lipids). After centrifugation, supernatants (10 L) were injected directly onto a 150 ϫ 3.0 -mm Prosphere HP C4 column (Grace). The column was eluted isocratically with an 80% mobile phase A (95:5:0.1 v/v/v 10 mmol/L ammonium acetate/methanol/acetic acid) for 2 min followed by a linear gradient to 80% mobile-phase B (99.9:0.1 v/v methanol/acetic acid) over 1 min, a linear gradient to 100% mobile phase B over 12 min, then 10 min at 100% mobile-phase B. MS analyses were carried out using electrospray ionization and Q1 scans in the positive ion mode. Ion spray voltage was 5.0 kV and source temperature was 400°C.
Before each set of analyses, LC-MS/MS system sensitivity and chromatography quality were checked by analyzing reference samples: synthetic mixtures of reference metabolites (Sigma) and a lipid extract prepared from a pooled human plasma stock (Bioreclamation). During the application of each method, internal standard peak areas were monitored for QC. Moreover, reference pooled plasma samples (which were not blinded to the laboratory, unlike the QC pooled plasma samples in the blinded duplicates pilot) were included in each set of analyses, with samples inserted at the beginning and after sets of approximately 20 study samples. The reproducibility of each metabolite in the pooled plasma samples was determined to confirm the overall quality of the analyses (see online Supplemental Tables 4 -6). MultiQuant 1.2 software (AB SCIEX) was used for automated peak integration and metabolite peaks were manually reviewed for quality of integration and compared against a known standard to confirm identity. Metabolites with a signal-to-noise ratio Ͻ10 were considered unquantifiable. For these analyses, metabolite signals were retained as measured LC-MS/MS peak areas, which are proportional to metabolite concentration and are appropriate for metabolite clustering and correlative analyses.
STATISTICAL ANALYSIS
The 3 pilot studies were completed sequentially. For these analyses, we considered 257 metabolites that were measured in both the delayed processing and withinperson reproducibility over time pilots. For presentation purposes, metabolites were classified into 11 categories (see online Supplemental Tables 7-8): lipids and lipid metabolites (n ϭ 118); bile acids (n ϭ 5); amino acids (n ϭ 22); amino acid derivatives (n ϭ 28); amines (n ϭ 7); alcohols (n ϭ 3); carbohydrates and intermediates (n ϭ 13); organic acids (n ϭ 17); purines, pyrimidines, and derivatives (n ϭ 28); vitamins (n ϭ 7); and other (n ϭ 9). In each pilot study, we excluded metabolites that were unquantifiable in Ͼ50% of samples or had CVs Ͼ20% in the analyzing laboratory's reference pooled plasma samples (see online Supplemental Tables 4 -6) from statistical analyses; thus, the number of metabolites included in each analysis varies slightly. Of note, 16 metabolites were either unquantifiable in Ͼ50% of samples or had CVs Ͼ20% in the reference pooled plasma samples across all 3 pilot studies and therefore do not have available data for any of the 3 pilots.
To quantify interassay reproducibility, we used data from the blinded duplicate participant samples and QC replicates in the 3 pilot studies. For each metabolite, we calculated the CV for each participant or QC pool by dividing the SD by the mean peak area and multiplying by 100. To calculate the mean interassay CV, we averaged the CVs across participants and QC pools. Within each metabolite category, we averaged mean CVs across metabolites and calculated the percentage of metabolites with mean CVs Ͻ20%, a level generally considered acceptable with respect to laboratory error (22 ) . To evaluate whether assay variability differed by anticoagulant type or fasting status, CVs were assessed separately for EDTA and heparin samples and for blood samples donated by participants fasting Ն8 and Ͻ8 h. Regarding fasting status, we hypothesized that CVs might be higher in samples donated after Ն8 vs Ͻ8 h fasting because of lower concentrations of some metabolites with longer fasting time. To assess whether platform reproducibility was associated with metabolite peak area, we calculated Spearman correlation coefficients of metabolites' mean peak area with mean CV.
To assess metabolite reproducibility in blood samples processed after a delay, we calculated Spearman correlation coefficients to compare rankings of metabolite peak areas in samples processed immediately vs 24 or 48 h after collection. Additionally, to provide a summary measure accounting for the impact of withinperson relative to total variation in metabolite peak areas, as well as the absolute values of metabolite peak areas across processing times, we calculated intraclass correlation coefficients (ICCs), defined as the betweenperson variance divided by the sum of the within-and between-person variances; between-and withinperson variances were estimated using a mixed model, with participant as the random variable. Metabolite peak areas were natural log transformed for ICC calculations to improve the normality of peak area distributions. ICCs in samples processed immediately vs 24 h after collection as well as across all 3 processing times were calculated. An ICC Ն0.75 indicates excellent reproducibility, 0.4 -0.75 indicates fair to good reproducibility, and Ͻ0.4 indicates poor reproducibility (22 ) . Spearman correlation coefficients and ICCs were calculated separately for EDTA and heparin samples.
To assess metabolite peak area reproducibility over 1-2 years, Spearman correlation coefficients and ICCs were calculated as described above. In additional analyses, we calculated ICCs adjusted for age at initial blood draw (continuous), body mass index (BMI) at initial blood draw (continuous, kg/m 2 ), and time between collections (continuous) by including these variables in the mixed model as fixed effects. For these analyses, 0.4 was considered the lower bound of acceptability; for context, an ICC of 0.4 would attenuate a true odds ratio of 2.0 to an observed odds ratio of 1.3 in epidemiologic studies (7, 22 ) . Also, for comparison, ICCs for serum cholesterol measured 1 year apart and plasma prolactin measured 2-3 years apart are 0.65 and 0.45, respectively; both have been associated with disease in epidemiologic studies (23, 24 ) .
We conducted secondary analyses to examine the influence of fasting status and anticoagulant type on metabolite peak areas. For each metabolite, we averaged metabolite peak areas separately among participants in the blinded duplicates pilot who fasted Ն8, 6 -7, and 4 -5 h before blood collection. Then, we calculated the percentage difference in mean metabolite peak areas between the group fasting 6 -7 or 4 -5 h vs Ն8 h. We also compared metabolite peak areas by anticoagulant type in samples processed immediately after collection among 4 individuals in the delayed processing pilot study who donated both heparin and EDTA blood samples. Percentage differences in metabolite peak areas in heparin vs EDTA were calculated by subtracting the EDTA peak area from the heparin peak area and dividing by the EDTA peak area.
Results
Characteristics of participants included in each pilot study are shown in Table 2 . Pilot study results for individual metabolites are provided in online Supplemental Tables 7 and 8 .
BLINDED DUPLICATES PILOT
The majority of metabolites (92%) had CVs Ͻ20%, indicating acceptable interassay reproducibility (Table  3) . Purines, pyrimidines, and derivatives were measured with the most variability, with 55% of CVs Ն20%. CVs generally were comparable between EDTA and heparin samples. However, variability appeared greater in heparin vs EDTA samples for bile acids and carbohydrates and intermediates. Fasting status did not appear to affect laboratory variability for most metabolites, although CVs tended to be higher in samples donated after Ն8 vs Ͻ8 h fasting, possibly because of lower concentrations of some metabolites in the fasting condition. Larger metabolite peak area tended to be associated with lower CVs, with an overall correlation of Ϫ0.54.
When comparing metabolite peak areas across fasting status categories, we noted small differences in measured peak areas for most metabolites (Table 4) . Among all metabolites, median differences in metabolite peak area were Ϫ1% and 6% comparing participants fasting for 6 -7 and 4 -5 h vs Ն8 h, respectively, although ranges were wide (10th to 90th percentile, Ϫ17% to 30% and Ϫ13% to 27%, respectively).
DELAYED PROCESSING PILOT
Among all metabolites, Ͼ75% had Spearman correlations or ICCs Ն0.75 when we compared samples processed immediately vs 24 h after collection, indicating good to high reproducibility of most metabolites in whole blood samples after a 1-day processing delay (Table 5 ). However, Ͻ15% of purines, pyrimidines, and derivatives and Ͻ30% of carbohydrates and intermediates had Spearman correlations or ICCs Ն0.75. Reproducibility over processing delays was similar, although slightly reduced, when we compared metabolite peak areas in samples processed immediately vs after 48 h (data not shown).
We compared metabolite peak areas by anticoagulant type among 4 noncohort participants, using samples processed immediately after collection (See online Supplemental Table 9 ). Among all metabolites, the median difference in peak area in heparin vs EDTA samples was 4% (10th to 90th percentile, Ϫ18% to 50%). In 116 (100) 8 (2) (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) (13) (14) (15) (16) (17) (18) (19) (20) (21) 115 (99) 8 (2) (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) (13) (14) (15) (16) (17) (18) (19) 116 (100) 10 (2-25) 112 (97) 8 (2-17) 116 (100) Bile acids 4 16 (8-22) 3 (75) 6 (2-14)
4 (100) 18 (9-24) 1 (25) 32 (16-39) 1 (25) 6 (2-14) 4 (100)
Amino acids 22 7 (3-13)
22 (100) 6 (3-12)
22 (100) 7 (3-13) 22 (100) 6 (3-10)
22 (100) 7 (3-15)
(100)
Amino acid derivatives 6 (100) 6 (3-14)
6 (100) 7 (4-13) 6 (100) 6 (3-13)
6 (100) 7 (3-14) 6 (100) Alcohols 3 11 (10) (11) (12) 3 (100) 9 (3-13)
3 (100) 11 (9-14) 3 (100) 17 (12-26) 2 (67) 7 (2-10)
Carbohydrates and intermediates 9 (82) 12 (6-22) 10 (91) 13 (5-26) 8 (73) 9 (2-17) 10 (91) Purines, pyrimidines, and derivatives 5 (45) 27 (5-55) 4 (36) 30 (7-64) 3 (27) 13 (1-42) 6 (55)
Vitamins 5 16 (7-24) 3 (60) 14 (7) (8) (9) (10) (11) (12) (13) (14) (15) (16) (17) (18) (19) 4 (80) 16 (5-26) 3 (60) 23 (10-45) 2 (40) 13 ( 190 (93) 11 (2-61) 184 (90) 12 (2-64) 173 (84) 9 (1-44) 193 (94) a Number of metabolites included in analyses (45 metabolites excluded because the metabolite CV in the analyzing laboratory's reference pooled plasma samples was Ͼ20%; 7 metabolites excluded because there was no quantifiable signal in Ͼ50% of samples).
8 of 11 metabolite categories, median percentage differences in peak areas were Ͻ15%, although percentage differences were variable in certain categories, most notably, purines, pyrimidines, and derivatives.
WITHIN-PERSON REPRODUCIBILITY OVER TIME PILOT
Among participants who donated 2 blood samples 0.8 -2.3 years apart, women were on average 1.4 years older and their mean (range) BMI was 0.17 kg/m 2 (Ϫ1.8, ϩ2.7 kg/m 2 ) higher at the second vs first blood collection. Comparing measurements in the 2 samples, 90% of metabolites had Spearman correlations or ICCs Ն0.40, indicating that a single measurement may reasonably represent longer-term levels in epidemiologic studies (Table 6 ). However, we observed less robust within-person reproducibility for carbohydrates and intermediates; amines; and purines, pyrimidines, and derivatives (Spearman correlations or ICCs Ͻ0.40 for 29%-60% of metabolites in the category). Nevertheless, samples in this pilot were subject to delayed processing, which may have added variability to metabolite measurements for these categories, and impacted estimates of within-person reproducibility over time.
In additional analyses, we adjusted the ICCs for factors that could potentially affect reproducibility (age, BMI, time between blood collections). ICCs tended to attenuate; 74% of metabolites had ICCs Ն0.40 compared with 83% in unadjusted analyses (Table 6 ; also see online Supplemental Table 8 ).
Between-person variability in metabolites explained by adjustment factors may explain the attenuation in ICCs.
Discussion
To determine the suitability of an LC-MS/MS metabolomics platform for use in large-scale epidemiologic studies, we performed 3 pilot studies of over 250 metabolites measured in archived human plasma. These pilots were designed to evaluate sources of measurement error of particular concern in epidemiologic studies: interassay reproducibility, reproducibility over processing delays, and within-person reproducibility over time. Approximately 90% of metabolites were measured with CVs Ͻ20%; CVs tended to be lower for metabolites with larger peak areas. CVs generally were comparable by anticoagulant type or fasting status, although specific metabolites demonstrated differences. This finding suggests systematic differences between referent and comparison groups in anticoagulant type or fasting time have the potential to introduce bias in epidemiologic studies.
Our delayed processing pilot, in which approximately 75% of metabolites had Spearman correlations or ICCs Ն0.75 when we compared immediately processed samples to those processed after a 24-h delay, highlighted a set of metabolites (e.g., carbohydrates and purines, pyrimidines, and derivatives) that are un- a Number of metabolites included in analyses (53 metabolites excluded because they were not measured in the blinded duplicates pilot; 39 metabolites excluded because the metabolite CV in the analyzing laboratory's reference pooled plasma samples was Ͼ20%; 7 metabolites excluded because there was no quantifiable signal in Ͼ50% of samples). b Comparisons of metabolite concentrations among 30 participants, of which 10 each provided plasma 4 -5 h, 6 -7 h, and Ն8 h after their last meal. (82) 15 (68) 21 (95) 20 ( 3 (21) 4 (29) 8 (57) 9 ( Intraclass correlations, defined as the between-person variance divided by the sum of the between-and within-person variance, were calculated using natural log transformed metabolite LC-MS/MS peak areas.
likely to be accurately measured in studies with delayed processing. Poor results for carbohydrates are expected given that the glycolytic processes in whole blood and ongoing enzymatic reactions in whole blood likely contribute to instability of purines and pyrimidines (25 ) . Inclusion of these metabolites may increase the likelihood of false-negative results and, in studies of hundreds of analytes, may increase the penalty for multiple testing without contributing meaningful data. Ninety percent of metabolites demonstrated Spearman correlations or ICCs Ն0.40 when we compared measurements in samples donated 0.8 -2.3 years apart. However, ICCs may vary between individuals who did and those who did not experience changes in health between blood collections (26 ), and our findings represent average results among all women in the study population. Nonetheless, our results suggest that, within the context of an epidemiologic study in which attenuation of effect estimates is a key concern, a single plasma measurement likely is reasonably representative of longer-term exposure for the vast majority of metabolites on the platform. This is of particular importance for prospective epidemiologic studies of chronic diseases with long latency periods.
Findings from previous studies support the results we observed for the best-performing metabolite categories, including lipids (23, (27) (28) (29) (30) (31) and amino acids (32 ) . Of note, several individual metabolites [e.g., ADMA (asymmetric dimethylarginine), homocysteine, urate, and folate] performed poorly in these metabolite profile pilot studies but have had acceptable results when measured using single assays. For example, folate concentrations were largely undetectable with the metabolomics platform but were measurable in NHS samples using a radioassay kit (33 ) . Such differences in performance likely reflect differences in assay optimization between the metabolomics platform and a single assay.
Several limitations of our study should be considered. First, although we assessed interassay reproducibility, CVs may vary by laboratory and project size. Investigators should evaluate CVs in replicate QC samples in their own studies; including 10% of the total sample size as QCs is one standard approach (6 ) . Our analysis of differences in LC-MS/MS peak area by fasting status evaluated separate groups of individuals, rather than changes within individuals; additional studies are needed to better understand this issue (34 ) . Also, because our examination of long-term withinperson reproducibility of metabolite measurements used actual NHS samples, variability in metabolite measurements due to delayed processing was incorporated into the within-person variance estimates, possibly causing underestimation of reproducibility over a Intraclass correlations, defined as the between-person variance divided by the sum of the between-and within-person variance, were calculated using natural log transformed metabolite LC-MS/MS peak areas. b Number of metabolites included in analyses (31 metabolites excluded because the metabolite CV in the analyzing laboratory's reference pooled plasma samples was Ͼ20%; 16 metabolites excluded because there was no quantifiable signal in Ͼ50% of samples).
time for metabolites during the processing delay. Finally, we were not able to assess certain metabolites because of undetectable concentrations in our participants. However, when measuring over 250 metabolites, it is expected that a small proportion will not be detectable in a particular population. In summary, our pilot studies indicated that the large majority of metabolites included on a highthroughput metabolomics platform could be accurately measured in conditions mimicking those of prospective epidemiologic studies. Most metabolites, particularly lipids and lipid metabolites, amino acids, and bile acids, were measured with acceptable laboratory variability and were reproducible over processing delays and within individuals over 1-2 years. However, our results also suggested that metabolite profiles involving carbohydrates and intermediates; purines, pyrimidines, and derivatives; and amines may be more difficult to evaluate in epidemiologic studies in which blood samples were processed after a 24-h or longer delay. Future studies are needed to obtain estimates of long-term within-person reproducibility of metabolites in samples processed immediately after collection.
